Technical Analysis for SHPH - Shuttle Pharmaceuticals Holdings, Inc.
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Weak or Absent | N/A | Down | Down |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| Fell Below 50 DMA | Bearish | 0.00% | |
| MACD Bearish Centerline Cross | Bearish | 0.00% | |
| Wide Bands | Range Expansion | 0.00% | |
| Gapped Down | Weakness | 0.00% | |
| MACD Bullish Centerline Cross | Bullish | -16.12% | |
| Inside Day | Range Contraction | -16.12% | |
| Wide Bands | Range Expansion | -16.12% | |
| Upper Bollinger Band Touch | Strength | -16.12% | |
| Pocket Pivot | Bullish Swing Setup | -17.81% | |
| Wide Bands | Range Expansion | -17.81% |
Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App
| Alert | Time |
|---|---|
| Fell Below 50 DMA | about 8 hours ago |
| 50 DMA Support | about 9 hours ago |
| Down 1 ATR | about 9 hours ago |
| 60 Minute Opening Range Breakdown | about 13 hours ago |
| Fell Below 10 DMA | about 13 hours ago |
Free Daily (Stock) Chart Reading
Let us help you stay on top of your investments. We will alert you to important technical developments on your
portfolio & watchlist.
Configure default chart indicators
Basic chart:
- Earnings date: ???
Shuttle Pharmaceuticals Holdings, Inc., through its subsidiary, Shuttle Pharmaceuticals, Inc., focuses on the discovery, development, and commercialization of drugs for sensitizing cancers to radiation therapy. Its products in clinical stage include Ropidoxuridine, an oral halogenated pyrimidine to treat patients with brain tumors and soft tissue sarcomas; and Doranidazole, an injectable hypoxic cell radiation sensitizer for treatment of pancreatic, lung, and liver cancers. The company was founded in 2012 and is based in Rockville, Maryland.
Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic
Keywords: Medicine Cancer Radiation Radiation Therapy Sarcoma Brain Tumor Liver Cancer Soft Tissue Sarcoma
Classification
Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic
Keywords: Medicine Cancer Radiation Radiation Therapy Sarcoma Brain Tumor Liver Cancer Soft Tissue Sarcoma
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 126.26 |
| 52 Week Low | 1.35 |
| Average Volume | 1,825,433 |
| 200-Day Moving Average | 0.00 |
| 50-Day Moving Average | 2.07 |
| 20-Day Moving Average | 2.00 |
| 10-Day Moving Average | 2.19 |
| Average True Range | 0.34 |
| RSI | 46.81 |
| ADX | 24.12 |
| +DI | 28.24 |
| -DI | 16.33 |
| Chandelier Exit (Long, 3 ATRs) | 1.84 |
| Chandelier Exit (Short, 3 ATRs) | 2.62 |
| Upper Bollinger Bands | 2.48 |
| Lower Bollinger Band | 1.51 |
| Percent B (%b) | 0.53 |
| BandWidth | 48.72 |
| MACD Line | 0.00 |
| MACD Signal Line | -0.06 |
| MACD Histogram | 0.0604 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 2.59 | ||||
| Resistance 3 (R3) | 2.65 | 2.53 | 2.50 | ||
| Resistance 2 (R2) | 2.53 | 2.38 | 2.50 | 2.47 | |
| Resistance 1 (R1) | 2.28 | 2.29 | 2.21 | 2.22 | 2.44 |
| Pivot Point | 2.15 | 2.15 | 2.12 | 2.12 | 2.15 |
| Support 1 (S1) | 1.90 | 2.01 | 1.84 | 1.84 | 1.62 |
| Support 2 (S2) | 1.77 | 1.92 | 1.74 | 1.59 | |
| Support 3 (S3) | 1.52 | 1.77 | 1.56 | ||
| Support 4 (S4) | 1.47 |
